NRC Health 2026: Revenue $35.39M, EPS ($0.15) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.NRC Health reported Q2 2026 results with revenue of $35.39M, up 4% YoY, but posted a net loss of ($3.28M) and diluted EPS of ($0.15), compared to a minor loss in the prior year. Revenue growth was driven by recurring revenue and new customers. TRCV rose 11% to $151.9M. Increased investments in technology, R&D, and non-recurring stock-based compensation impacted operating margins.
NRC Health reported results for the quarter ended 2026 with revenue of $35.39M, up 4% from $34.04M a year earlier, and a net loss of ($3.28M) versus a loss of ($106K) in the prior-year quarter; diluted EPS was ($0.15) compared with ($0.01) a year ago.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $35.39M | $34.04M | 4% |
| Net income² | ($3.28M) | ($106K) | (2997.2%) |
| Diluted EPS³ | ($0.15) | ($0.01) | (1400%) |
¹ Reported as “Revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Earnings (loss) per share of common stock”.
Business Highlights
- Revenue growth of about 4% year-over-year was driven by higher recurring revenue from existing customers and additions of net new customers.
- The company introduced approximately $0.7M of contra‑revenue related to agent arrangements, reflecting increased third‑party solution facilitation.
- Total recurring contract value (TRCV) rose 11% YoY to $151.9M, indicating a stronger contracted recurring pipeline and improved revenue visibility.
- Management increased technology and delivery investments, including higher contractor, subscription and R&D costs; headquarters renovation completed in June 2025.
- Executive equity amendments and related transition costs raised stock‑based compensation and affected operating margins; these were characterized as non‑recurring items.
Original SEC Filing: NRC HEALTH [ NRC ] - 10-Q - Aug. 04, 2026